Laddar...

Sorafenib exerts anti-glioma activity in vitro and in vivo

Despite conventional treatment strategies glioblastoma, the most common malignant primary brain has a bad prognosis with median survival times of 12-15 month. In this study, the efficacy of sorafenib (Nexavar, BAY43-9006), a multikinase inhibitor, on glioblastoma cells was evaluated both in vitro an...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Siegelin, Markus D., Raskett, Christopher M., Gilbert, Candace A., Ross, Alonzo H., Altieri, Dario C.
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2010
Ämnen:
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC3198851/
https://ncbi.nlm.nih.gov/pubmed/20470863
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.neulet.2010.05.009
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!